Arcus Biosciences, Inc.
Clinical trials sponsored by Arcus Biosciences, Inc., explained in plain language.
Biotech developing cancer immunotherapies.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New combo therapy aims to slow advanced kidney cancer
Disease control Recruiting nowThis study tests whether adding the experimental drug casdatifan to the standard drug cabozantinib can slow cancer growth better than cabozantinib alone in people with advanced clear cell kidney cancer. About 720 adults whose cancer worsened after prior immunotherapy will receive…
Phase: PHASE3 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat kidney cancer
Disease control Recruiting nowThis early-stage study tests a new drug called casdatifan (AB521) alone or combined with other cancer drugs in people with advanced clear cell kidney cancer or other solid tumors. The main goals are to check safety and find the right dose. About 362 participants will take part.
Phase: PHASE1 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC